HSC professor among international researchers using stem cells to combat COVID-19 pneumonia

By Diane Smith

Dr. Jin Covid Web

When news of the coronavirus emerged from Wuhan, China, Kunlin Jin, PhD, and a team of international researchers quickly joined forces to fight the mysterious disease.

Dr. Jin relied on his more than 20 years of knowledge about stem cells to work with an international team driven to save lives. He used the messaging app WeChat to bridge the distance between his laboratory at The University of North Texas Health Science Center at Fort Worth, and experts in China.

“A lot of people are trying find the answers,” said Dr. Jin, who spends most of his time working alongside graduate students on stem cell therapies to fight strokes at the HSC Institute for Healthy Aging.

Dr. Jin and his colleagues used a 21st century solution to address an unfolding pandemic. Instead of finding the next Tamiflu, they started testing whether stem cells can be used to boost a person’s immune system to ward off COVID-19 pneumonia.

Dr. Jin said early findings are promising, and their international effort to test this treatment continues as a long-term study with more patients in China.

“I am proud to be part of the team I work with to fight COVID-19,” Dr. Jin said. “Our study showed that intravenous infusion of clinical-grade human mesenchymal stem cells is a safe and efficient approach for treating patients with COVID-19 pneumonia, including in elderly patients displaying severe pneumonia.”

Working in real time

Dr. Jin and his colleagues worked in real time. He said they had a sense of urgency because the outbreak “posed great threats to global public health.”

As part of the experimental treatment, stem cells were injected intravenously into the bloodstream of seven patients in Beijing who were severely sick. Three patients were injected with a placebo, the study states.

The people tested were patients at YouAn Hospital in Beijing, Dr. Jin said. Testing began on Jan. 30, according to the study.

The seven patients who received stem cells were successfully treated and were discharged from the hospital within 14 days, Dr. Jin said. Of the patients who received the placebo, one died, one became severe and the third had Acute Respiratory Distress Syndrome (ARDS).

Before stem cells can be used in the United States to fight the virus, there would have to be clinical trials in this country and approval from the U.S. Food and Drug Administration.

The team’s findings will be included in the upcoming April 2020 issue of Aging and Disease (www.aginganddisease.org).” The article is titled: “Transplantation of ACE2-Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.”

‘A desperate need for anything’

As international headlines about the virus evolved, research and clinical colleagues from several countries, including the United States, United Kingdom, South Korea, China and Russia pooled their expertise.

The team is made up of medical researchers who meet at conferences and often discuss science, aging and health-related issues. They work together as part of the International Society on Aging and Disease, which was founded by Dr. Jin.

When coronavirus strikes, it can result in a virus-induced cytokine storm – the term used when the immune system is so triggered that fluids fill the lungs and tissues are damaged.

“This is thought to be one of the main reasons why the COVID-19 pneumonia actually kills an individual – this storm of activity trying to fight the virus,” said David P. Siderovski, PhD, Professor and Chair Pharmacology & Neuroscience in HSC’s Graduate School of Biomedical Sciences.

“No specific drugs or vaccines are available to cure the patients with COVID-19 infection,” according to the journal article. “Hence, there is a large unmet need for a safe and effective treatment for COVID-19 infected patients, especially the severe cases.”

Additionally, finding antivirals for patients with COVID-19 is a difficult task, Dr. Siderovski said.

“When HIV broke in the 1980s, we scrambled to make AZT (azidothymidine),” he said, adding that researchers are trying different ideas to combat the virus. “There is a desperate need for anything – anything experimental, anything that could be tried off the shelf to address COVID-19 pneumonia.”

Recent News

Clearfield
  • Our People
|Sep 29, 2023

Dr. Michael Clearfield the inaugural winner of the Beyer, Everett, and Luibel Memorial Medal

For more than two decades, Dr. Michael B. Clearfield, DO, MACOI, FACP, has developed the Department of Internal Medicine and Geriatrics at the Texas College of Osteopathic Medicine into one of the largest and most productive academically in the osteopathic profession, serving as the chair from 1982-...
Kari Northeim 2 (002)[66]
  • Our People
|Sep 28, 2023

HSC’s Dr. Kari Northeim and Parker County collaborators awarded SAMHSA grant for rural EMS training and education

Dr. Kari Northeim, School of Public Health assistant professor of population and community health at The University of North Texas Health Science Center at Fort Worth, has been awarded the SAMHSA Rural EMS Training and Education grant in conjunction with HSC community partners, Parker County Hospi...
Graci Finco
  • Research
|Sep 28, 2023

SBS researchers publish innovative study in Nature Scientific Reports 

People with leg amputations, including those with diabetes, run the risk of overuse injuries like osteoarthritis, muscle atrophy or bone breaks in their intact limbs.   Now, new research is quantifying the impacts of amputations and diabetes, a leading cause of amputation, on those overuse ...
Frank Filipetto Cropped For Social
  • On Campus
|Sep 28, 2023

HSC’s Texas College of Osteopathic Medicine to host symposium on ‘Creating Change in Health Care Delivery’

Americans have soured on the U.S. health care system, according to a Gallup poll taken earlier this year. Most of those surveyed rate health care quality as subpar, including 31% saying it is “only fair” and 21% — a new high — calling it “poor.” The U.S. ranked nearly last compared w...